- Active not recruitingPHASE2
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
This study looks at new treatments for moderate to severe eczema (atopic dermatitis). It checks how well a drug called Lutikizumab works, either alone or with other treatments, and if it's safe. Participants will get injections and have regular check-ups.
For: Atopic DermatitisUnited States · Japan · South Korea - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
For: Crohn's DiseaseUnited States · Austria · Belgium - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
For: Hidradenitis SuppurativaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
For: Ulcerative ColitisUnited States · Australia · Austria - Active not recruitingPHASE2
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
This study looks at a new drug, lutikizumab, for adults with moderate to severe hidradenitis suppurativa (HS). It focuses on people whose current treatments haven't worked well or who haven't tried certain biological therapies before. The aim is to see if lutikizumab can reduce HS symptoms and is safe to use.
For: Hidradenitis SuppurativaUnited States · Australia · Canada